RESUMO
BACKGROUND: Since the early 1980s, epidemiological evidence has suggested a connection between low calcium intake and preeclampsia The purpose of this meta-analysis is to summarize current evidence regarding calcium supplementation during pregnancy in predicting preeclampsia and associated maternal-fetal complications. METHODS: Literature revision of all RCT (random allocation of calcium versus placebo) available in MEDLINE/PUBMED up to 2/29/2012 regarding calcium supplementation during pregnancy for preventing preeclampsia. We used the Mantel-Haenszel's Method for four subgroup of patients: Adequate calcium intake; Low calcium intake; Low risk of preeclampsia; High risk of preeclampsia. We considered p < 0.05 as significant. RESULTS: There is no consensus in Literature about: (1) the efficacy of calcium supplementation in the prevention of preeclampsia, (2) other/adverse/long-term effects of calcium supplementation in pregnancy. CONCLUSIONS: Preeclampsia is likely to be a multifactorial disease. However, inadequate calcium intake represents a factor associated with an increased incidence of hypertensive disease. The results of our meta-analysis demonstrate that the additional intake of calcium during pregnancy is an effective measure to reduce the incidence of preeclampsia, especially in populations at high risk of preeclampsia due to ethnicity, gender, age, high BMI and in those with low baseline calcium intake.
Assuntos
Cálcio da Dieta/administração & dosagem , Pré-Eclâmpsia/tratamento farmacológico , Pré-Eclâmpsia/prevenção & controle , Cálcio da Dieta/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Feminino , Humanos , Pré-Eclâmpsia/epidemiologia , Gravidez , Fatores de Tempo , Resultado do TratamentoRESUMO
Gestrinone has been shown to reduce uterine volume and stop bleeding in women with uterine leiomyomata. In the present study, we demonstrated a reduction in the volume of uterine myomas and in the uterine artery blood perfusion over a 6-month period of gestrinone administration in premenopausal women.
Assuntos
Antagonistas de Estrogênios/uso terapêutico , Gestrinone/uso terapêutico , Leiomiomatose/irrigação sanguínea , Leiomiomatose/tratamento farmacológico , Neoplasias Uterinas/irrigação sanguínea , Neoplasias Uterinas/tratamento farmacológico , Adulto , Feminino , Humanos , Leiomiomatose/diagnóstico por imagem , Pré-Menopausa , Fluxo Sanguíneo Regional/efeitos dos fármacos , Fatores de Tempo , Resultado do Tratamento , Ultrassonografia , Neoplasias Uterinas/diagnóstico por imagemRESUMO
The aim of the present study was to examine the relationship between Mullerian-inhibiting substance (MIS) levels and metabolic characteristics in women with polycystic ovary syndrome. Increased ovarian MIS production may exert a paracrine negative control on follicle growth sufficiently to prevent selection of a dominant follicle.
Assuntos
Glicoproteínas/sangue , Síndrome do Ovário Policístico/sangue , Hormônios Testiculares/sangue , Adulto , Hormônio Antimülleriano , Glicemia/metabolismo , Índice de Massa Corporal , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Hormônio Foliculoestimulante/líquido cefalorraquidiano , Humanos , Insulina/sangue , Resistência à Insulina/fisiologia , Hormônio Luteinizante/sangue , Síndrome do Ovário Policístico/líquido cefalorraquidiano , Globulina de Ligação a Hormônio Sexual/metabolismo , Estatísticas não Paramétricas , Testosterona/sangueRESUMO
OBJECTIVE: To determine if plasma and amniotic fluid levels of intercellular adhesion molecule-1 (ICAM-1) at 16 weeks' gestation could be predictive of preeclampsia or intrauterine growth retardation (IUGR). STUDY DESIGN: A retrospective analysis was undertaken in 44 serum samples stored for Down's syndrome screening at 16 weeks' gestation and 44 amniotic fluid samples obtained by midtrimester amniocentesis. RESULTS: No significant difference was found between women who subsequently developed preeclampsia or IUGR and the control group. CONCLUSION: This study failed to demonstrate that ICAM-1 may be an early serum marker of preeclampsia or an amniotic fluid marker of IUGR.
